It is some time since the protracted negotiations with First Pharma were called off by First Pharma.
Having regard to the renowned dealmaking credentials of NAV’s Board, is it not high time that a worthwhile alternative deal was secured? Has NAV not been looking at and preparing for any backup deals during the year of failed negotiations with First Pharma? Or did it put all its eggs in one basket and become overconfident that no alternative would need to be prepared?
The company’s tenuous gold “prospect” is just an embrionic sideline. It must not be used just to signify the company’s continuing reason to be. NAV’s current skill-set, absent an established mining partner, falls outside that compatible with the identification of gold resources.
Let’s see some commercial skill successfully demonstrated very soon and positive news in the near future. One reads daily of successful young innovative companies who would benefit from an ASX listing.
NAV Price at posting:
0.8¢ Sentiment: Hold Disclosure: Held
